Eli Lilly and Company (SNSE:LLYCL)
Chile · Delayed Price · Currency is CLP | Market Cap | 754.00T +3.9% |
| Revenue (ttm) | 67.18T +47.4% |
| Net Income | 23.50T +127.6% |
| EPS | 26,174.64 +129.1% |
| Shares Out | n/a |
| PE Ratio | 32.08 |
| Forward PE | 25.41 |
| Dividend | 5,729.16 (0.67%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 100 |
| Average Volume | 135 |
| Open | 857,100 |
| Previous Close | 874,000 |
| Day's Range | 849,300 - 860,000 |
| 52-Week Range | 608,400 - 1,034,500 |
| Beta | n/a |
| RSI | 51.18 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake
Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the U.S. in the fourth week, a modest uptake compared to rival Novo Nordisk's Wegovy pill, analysts said.
Eli Lilly price target raised to $1,235 from $1,183 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly (LLY) to $1,235 from $1,183 and keeps a Buy rating on the shares. The firm updated its model
Novo (NVO) and Lilly (LLY) Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential
Shares of Novo Nordisk ($NVO) and Eli Lilly & Co. ($LLY), two of the world’s largest drugmakers, rose slightly on Wednesday after data showed strong demand for their new oral
Novo and Lilly gain on signs weight-loss pills could expand the market
Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricin...
Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
Eli Lilly (LLY) Raises Bet to $21B as Obesity Pill War with Novo Nordisk Intensifies
U.S. pharma giant Eli Lilly ($LLY) has pumped another $4.5 billion investment into its manufacturing facilities in Indiana, a key anchor of its domestic manufacturing buildout. The figure has raised
Eli Lilly commits additional $4.5B across Indiana manufacturing sites
Eli Lilly (LLY) and Company announced an additional $4.5B investment across two of its three Lebanon sites-bringing the company’s total Indiana capital expansion commitments since 2020 to more than $2...
Lilly commits additional $4.5 billion across Indiana manufacturing sites
Eli Lilly said on Wednesday it would commit an additional $4.5 billion investment across two of its three sites in Indiana, bringing the company's total capital expansion commitments in the...
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturin...
Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.
Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.
The Billion-Dollar Women's Health Market Driving A New Endometriosis Focus
The commercial success of GLP-1 therapies has reshaped the economics of modern pharmaceuticals. What began as a treatment pathway for type 2 diabetes and obesity has evolved into one of the most lucra...
Eli Lilly announces new long-term Omvoh data
New long-term data from Eli Lilly (LLY) show patients with moderately to severely active ulcerative colitis, or UC, treated with Omvoh achieved durable disease clearance through four years of continuo...
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring ...
Eli Lilly price target raised to $1,400 from $1,350 at Barclays
Barclays analyst Emily Field raised the firm’s price target on Eli Lilly (LLY) to $1,400 from $1,350 and keeps an Overweight rating on the shares. The firm increased estimates following
Lilly declares second-quarter 2026 dividend
INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common st...
Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’
RBC Capital notes that Eli Liily shares were down as much as 3% in pre-market trading amid reports of a single FAERS hepatic failure case reported for Foundayo, but tells
Eli Lilly fears for Foundayo ‘unfounded,’ says Wolfe Research
Wolfe Research notes that the FDA received data on April 30 via its FDA Adverse Event Reporting System suggesting that a patient dosed with Eli Lilly’s (LLY) Foundayo reported a
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
The Food and Drug Administration has recorded two ‘serious' cases in patients taking Eli Lilly's weight-loss pill.
Eli Lilly and Company Transcript: AGM 2026
The meeting covered director elections, management and shareholder proposals, and strong financial results, including a 45% revenue increase and major product launches. Shareholder proposals on board independence and lobbying transparency did not pass. Dividend growth and manufacturing expansion were highlighted.
Eli Lilly falls after FDA reports death of patient taking Foundayo
The FDA posted in its Adverse Event monitoring system that a 56-year-old male patient had hepatic failure following use of Eli Lilly’s (LLY) Foundayo. The case was reported to the
Evercore says report in FAERS has ‘potential to create confusion’ for Eli Lilly
Evercore ISI notes that the firm is “seeing something in the FDA adverse event database which has potential to create market confusion if not laid out with full background,” namely
'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds
For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, Deloitte has found. Pharma R&D returns for the world's top 20 pharma companies have improved...
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Lilly's obesity pill hits 5,612 prescriptions in third week after launch
Eli Lilly's newly launched oral weight loss drug was prescribed 5,612 times in the U.S. in the third week after its launch, according to analysts citing IQVIA data.
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.
Eli Lilly's stock is powering higher on fresh signs of booming demand for its weight-loss drugs. Will it be enough to drive a recovery for the stock?